Our improved understanding of biology has led us to some truly amazing new therapeutics and other life science breakthroughs. Yet, novel technologies can offer even more. What if somebody could tell you the quantities of nearly all the proteins in your experimental system, be it cell culture, plasma, or cancerous tissue? Would you listen?

Proteins are the functional units of life. Together they orchestrate most biological functions required for any cell, organ or organism to function. Our understanding of biological systems relies on the ability to directly quantify proteins on a proteome-wide scale.

Recent major advancements in mass spectrometry instrumentation and data analysis algorithms enable deep and reproducible quantification of entire proteomes. This next generation proteomics technology is used more and more for biomarker research, drug target discovery, pathway modeling, mechanisms of action studies and many other areas.

We believe that the decoding of the proteome will impact life sciences more than the genome revolution a decade ago. Join the proteomics revolution now!

Click for more information about Spectronaut™ Pulsar

Why proteomics?

Proteomics aims at understanding the proteome by enabling the unbiased and large-scale study of proteins. Watch the video to understand why next generation proteomics should be the technology of choice in studies involving multiplexed protein quantification.

Register to the webinar here!

What is proteomics?

Biognosys has developed a new way of measuring proteins on a large scale. We use cutting-edge mass spectrometry instrumentation for deep and reproducible quantification of entire proteomes. This innovative technology acquires peptide signals in parallel mode. The data is deconvoluted into individual protein quantities with our powerful pattern recognition algorithms.

Learn more about our technology

Example: Pharma lab

You have narrowed down the number of candidates for your coming drug to four. Your own assessment using transcriptomics is that sample A is the most effective candidate, whereas sample B is considered second best. You turn to Biognosys for a second opinion.

Our analysis shows that sample A is likely to have side-effects and therefore a poor candidate for further research. Sample B, however, indicates a sufficiently good effect, with a low risk of side-effects, proving to be the optimal candidate to proceed with.

Your lab decides to go on with sample B, thus avoiding unnecessary re-starting or wasted research and development work further down the line.

Customer analysis
using transcriptomics

First choice:
Sample A – very high effect, low risk of side-effects
Second choice:
Sample B – high effect, low risk of side-effects

Biognosys analysis
using next-generation proteomics

Second choice:
Sample A – very high effect, high risk of side-effects
First choice:
Sample B – high effect, low risk of side-effects
Register to the webinar here!

Biognosys proteomics platforms

Biognosys provides contract research services for high-content protein quantification from any species in any biological matrix to facilitate translational research.

Can identify global proteome changes or regulated pathways across samples by complete profiling of up to 7,000 proteins per sample.

Allows sensitive and accurate quantification of proteins of interest and can solve limitations of antibody based assays.

Reveals compound-protein interactions in your samples and helps to identify drug targets.

Watch the video

Example: Pharma lab

You have narrowed down the number of candidates for your coming drug to four. Your own assessment using transcriptomics is that sample A is the most effective candidate, whereas sample B is considered second best. You turn to Biognosys for a second opinion.

Our analysis shows that sample A is likely to have side-effects and therefore a poor candidate for further research. Sample B, however, indicates a sufficiently good effect, with a low risk of side-effects, proving to be the optimal candidate to proceed with.

Your lab decides to go on with sample B, thus avoiding unnecessary re-starting or wasted research and development work further down the line.

Customer analysis
using transcriptomics

First choice:
Sample A – very high effect, low risk of side-effects
Second choice:
Sample B – high effect, low risk of side-effects

Biognosys analysis
using next-generation proteomics

Second choice:
Sample A – very high effect, high risk of side-effects
First choice:
Sample B – high effect, low risk of side-effects
Register to the webinar here!

It's easy to use our services!

You don’t need any costly equipment to benefit from the power of next generation proteomics. Trust our proteomics experts with your experiments instead so that you can focus on your research. Here is how easy it is.

1. Decide on the
platform

Depending on your research objective our experts will in collaboration with you identify which platform is the most suitable.

2. Send your samples

We operate a state-of-the-art proteomics lab and mass spectrometry facility for the analysis of your samples.

3. Participate in the process

We analyze the data with our powerful algorithms and present an interim report containing the detectable proteins and a quantitative preview.

4. Receive biological insights

We run the full analysis including downstream biological interpretation and present the final report containing the protein quantities across all samples, statistical and biological data analysis including QC metrics.

Download our services brochure (PDF)

On-demand webinars

Learn more about the power of next generation proteomics technology from the leaders in the field. Through our webinars you have the opportunity to listen to proteomics' most influential scientists:

“To what extent do mRNA levels determine protein concentrations?”

Presenter

Prof. Dr. Andreas Beyer, University of Cologne, Germany

Moderator

Dr. Oliver Rinner, Biognosys, Switzerland

Register and watch the webinar
“The quantitative proteotype: Measurement and biological significance”

Presenters

Prof. Dr. Ruedi Aebersold, ETH Zurich, Switzerland
Dr. Oliver Rinner, Biognosys, Switzerland

Moderator

Prof. Dr. Ernst Hafen, ETH Zurich, Switzerland

Register and watch the webinar
Register to the webinar here!

The benefits of next generation proteomics

It is high-content

Next generation proteomics can identify and quantify up to 10,000 proteins in a single run
Why is this important?
Researchers are trying to get an as complete view as possible of the proteome to truly understand the biological system that they are investigating.

How do we achieve it?
The number of identified and quantified proteins - the so-called coverage - that can be achieved in a single proteomics experiment has increased significantly over the last years. This development has been driven by higher performing mass spectrometers (more sensitive, faster) on the one hand and increasingly refined and optimized data acquisition and data analysis workflows on the other.

What examples do we have?
Working together with David Gomez-Varela from the Max Planck Institute Goettingen, researchers at Biognosys identified over 8,000 proteins in a single run and over 10,000 proteins cumulatively in 3 runs from murine cerebellum samples.
Download poster

It is highly reproducible

Proteins can be reliably identified and quantified across large sample sets
Why is this important?
High coverage alone is not enough, one needs to also reproducibly identify and quantify the proteins of interest. In most proteomics experiments the researcher will seek to compare different samples to each other, for example different patient samples, samples taken over a time course or samples treated with a test compound vs a control. Only a bioanalytical method that reliably measures the presence or absence of proteins will enable such comparisons across different samples.

How do we achieve it?
In the early days the mass spectrometry proteomic workflows were not optimized to its full potential. So-called shotgun proteomics experiments yielded long lists of identified proteins but only a part of these proteins could be reproducibly identified and quantified. Newer methods combine the high-content aspect of shotgun proteomics with the reproducibility of proteomics techniques known as “targeted proteomics”.

What examples do we have?
Oliver Rinner, CEO of Biognosys, has written a comprehensive review article about next generation proteomics comparing technologies and data-sets obtained with the new approach against traditional mass spectrometry techniques.
Download article

It is high-throughput

Hundreds of samples can be routinely analyzed
Why is this important?
With its high proteome coverage and high reproducibility next generation proteomics is an ideal tool to study larger sample numbers, for example to drive statistical power in a biomarker discovery experiment or to understand disease progression in larger patient cohorts.

How do we achieve it?
New chromatographic methods and columns that allow shorter gradients, in combination with faster mass spectrometers today enable the routine analysis of hundreds of samples.

What examples do we have?
In a recent study conducted by Biognosys and Nestle as a part of pan-European Diogenes project, 1,546 human plasma samples were analyzed within two months.
Download poster

It yields actionable results

Data visualization and analysis tools drive biological insight
Why is this important?
The data obtained in a proteomics experiments needs to be interpreted in the context of the original research question. Merely obtaining long lists of protein IDs and expression data can leave the researcher overwhelmed and diminish the usefulness of the data.

How do we achieve it?
Many options exist today for the visualization and functional interpretation of proteomics data (for example vulcano plots or gene ontology and pathway analysis, etc). The tools are easy to use and do not require an army of bioinformaticians to operate.

What examples do we have?
In a recent study we applied next generation proteomics to a small liver cancer pilot study, analyzing a set of three liver cancer samples as well as matched adjacent healthy tissue. Downstream analysis was performed with Biognosys’ Spectronaut followed by pathway analysis using pathway analysis tools to reveal important insights into liver cancer biology.
Download application note

It is affordable

Next generation proteomics costs about the same – and in some cases less – than transcriptomics
Why is this important?
In order to compete with other methods such as transcriptomics next-generation proteomics needs to be accessible with a reasonable cost-per-sample.

How do we achieve it?
Faster and more sensitive instruments in combinations with method innovation have created efficiencies and continuously driven the cost-per-sample down over recent years.

What examples do we have?
Contact us to receive an information about a price for your specific project.
Contact us

I'd like to know more!

Do you have a biological question or a proteomics project in mind? Are you curious and want to understand how our proteomics services can support you? Don’t hesitate to register here. We would be pleased to answer any questions you might have, no commitment from your side. We consider transparency, confidentiality, pro-active communication and structured project management key factors for a successful customer relationship.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Finally, some info about Biognosys

Biognosys is the leading proteomics company offering innovative services and products for highly multiplexed protein quantification. We are dedicated to transforming the life sciences with superior proteomics solutions. Biognosys’ next generation technology quantifies proteins with unbeatable precision and depth. Our solution relies on mass spectrometry, which allows simultaneous quantification of thousands of proteins in a single experiment. This new generation protein quantification technology is available to researchers worldwide through our contract research services or our portfolio of innovative reagent and software products.

Register to the webinar here!
Biognosys provides innovative services and products for protein discovery and quantification using cutting edge technology.
Copyright © 2017 Biognosys AG.